Congratulations to Rachel Flynn!
Rachel Flynn is the recipient of a 2026 Shipley Prostate Cancer Research Award and will study how cancer cells gain cellular immortality through the activation of the alternative lengthening of telomeres (ALT) pathway. ALT occurs in lethal metastatic prostate cancer, but the mechanisms promoting the activation of ALT are unknown. This research aims to identify the genetic basis of ALT activation in metastatic prostate cancer.